Florence Healthcare is a technology company.
Florence Healthcare has raised $116.0M across 4 funding rounds.
Florence Healthcare has raised $116.0M in total across 4 funding rounds.
Florence Healthcare has raised $116.0M in total across 4 funding rounds.
Florence Healthcare's investors include 8VC, Angular Ventures, Brewer Lane Ventures, Insight Partners, Lightspeed Venture Partners, MS&AD Ventures, Pitango Venture Capital, Silvertech Ventures, Ulu Ventures, Konstantin von Unger, Costanoa Ventures, Eclipse Ventures.
Florence Healthcare is a technology company headquartered in Atlanta, GA, that provides a leading Site Enablement Platform for clinical trials, digitizing workflows, automating operations, and enabling remote collaboration between research sites, sponsors, and CROs.[2][3][6] The platform serves over 65,000 trial sites across 90+ countries, supports 600+ sponsors, and facilitates 6.5 million workflows monthly, streamlining document management, compliance, eConsent, and remote monitoring to accelerate cures and improve patient outcomes.[3][4] It solves inefficiencies in clinical research by reducing startup times by 25%, document cycles by 40%, and enabling hybrid/decentralized trials, with a mission to drive research forward and double clinical trial output this decade.[4][7][9]
Founded in 2014 by co-founder and CEO Ryan Jones, Florence Healthcare emerged in Atlanta to address document and data flow bottlenecks between clinical research sites and sponsors.[4][5] The idea gained traction by pioneering remote connectivity and electronic workflow management, quickly becoming the industry standard with early adoption by 8,000+ sites in 30 countries by 2021.[4] Pivotal moments include innovations during the COVID-19 pandemic, such as Remote Site Monitoring for hybrid trials supporting vaccine research, and recent rebranding to emphasize global site-first solutions, backed by a network of 12,000+ sites in 45 countries.[2][4]
Florence rides the trend toward decentralized and hybrid clinical trials, accelerated by the pandemic's demand for remote monitoring and efficiency in a $50B+ industry plagued by slow startups and compliance hurdles.[4][7][8] Timing is ideal amid rising biopharma R&D pressures, regulatory pushes for faster approvals, and AI-driven automation, positioning Florence to connect fragmented ecosystems of 65,000+ sites and 600+ sponsors globally.[3] It influences the landscape by setting standards for site enablement, fostering partnerships that streamline workflows, and enabling innovations like COVID vaccine trials, ultimately speeding cures and reducing costs.[2][4][7]
Florence is poised for continued growth through AI enhancements, global expansion, and deeper integrations in decentralized research, potentially capturing more market share as trials shift remote.[3][9] Trends like AI-augmented intelligence and regulatory demands for speed will amplify its platform's value, evolving its role from workflow leader to indispensable trial intelligence hub. This builds on its site-centric foundation, reinforcing Atlanta's tech ecosystem while accelerating global patient outcomes.[2][6]
Florence Healthcare has raised $116.0M across 4 funding rounds. Most recently, it raised $27.0M Series C in June 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2022 | $27.0M Series C | 8VC, Angular Ventures, Brewer Lane Ventures, Insight Partners, Lightspeed Venture Partners, MS&AD Ventures, Pitango Venture Capital, Silvertech Ventures, Ulu Ventures, Konstantin von Unger | |
| May 1, 2021 | $80.0M Series C | 8VC, Angular Ventures, Brewer Lane Ventures, Costanoa Ventures, Eclipse Ventures, Insight Partners, Lightspeed Venture Partners, Liquid 2 Ventures, MS&AD Ventures, Pitango Venture Capital, Silvertech Ventures, The House Fund, Ulu Ventures, Virta Ventures, Konstantin von Unger | |
| Oct 1, 2019 | $7.0M Series B | Costanoa Ventures, Eclipse Ventures, Liquid 2 Ventures, The House Fund, Virta Ventures | |
| Aug 1, 2016 | $2.0M Seed | Costanoa Ventures, Eclipse Ventures, Liquid 2 Ventures, The House Fund, Virta Ventures |